Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Capital Expenditures (2022 - 2025)

Gossamer Bio's Capital Expenditures history spans 2 years, with the latest figure at $53000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures changed N/A year-over-year to $53000.0; the TTM value through Dec 2025 reached $79000.0, changed N/A, while the annual FY2025 figure was $79000.0, N/A changed from the prior year.
  • Capital Expenditures reached $53000.0 in Q2 2025 per GOSS's latest filing, up from $26000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $361000.0 in Q4 2022 to a low of -$228000.0 in Q3 2022.